SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
HBV inhibits SLC22A1 expression and SLC22A1 suppresses HBV by activating the JAK/STAT pathway. SLC22A1 is a predictor of the functional cure of CHB with pegIFNα-based treatment.
Authors
- Lili Wu (ORCID: https://orcid.org/0000-0002-1319-7274)
- Qiyi Zhao (ORCID: https://orcid.org/0000-0003-0649-0437)
- Bin Li (ORCID: https://orcid.org/0000-0002-7393-2111)
- Lin Li (ORCID: https://orcid.org/0000-0002-9719-4539)
- Huili Guo (ORCID: https://orcid.org/0000-0003-2315-0717)
- Xiaoquan Liu
- Na Gao (ORCID: https://orcid.org/0000-0002-8622-9273)
- Zhiliang Gao
- Xiuqing Pang
- Huiying Yu (ORCID: https://orcid.org/0009-0007-8113-1289)
Institutions
- Sun Yat-sen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1093/infdis/jiaf102
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35